Talphera is a specialty pharmaceutical company developing and commercializing innovative therapies for medically supervised settings. Its lead product candidate, Niyad (nafamostat mesylate), is a regional anticoagulant for continuous renal replacement therapy (CRRT), currently in a Phase 3 registrational trial (NEPHRO CRRT) with completion expected in 2026. A second candidate, LTX-608, is a nafamostat formulation for direct IV infusion targeting DIC, ARDS, acute pancreatitis, or anti-viral use. The company acquired Lowell Therapeutics in January 2022 and divested its DSUVIA product to Alora Pharmaceuticals in April 2023.
expected 2027-02-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001437749-26-009387 | EDGAR | 66K words |
| 2025-03-31 | 2024-12-31 | 0001437749-25-010250 | EDGAR | 70K words |
| 2024-03-06 | 2023-12-31 | 0001437749-24-006849 | EDGAR | 77K words |
| 2023-03-31 | 2022-12-31 | 0001437749-23-008737 | EDGAR | 95K words |
| 2022-03-10 | 2021-12-31 | 0001437749-22-005888 | EDGAR | 97K words |
| 2021-03-15 | 2020-12-31 | 0001437749-21-006074 | EDGAR | 94K words |
| 2020-03-16 | 2019-12-31 | 0001437749-20-005304 | EDGAR | 89K words |
| 2019-03-07 | 2018-12-31 | 0001437749-19-004353 | EDGAR | 90K words |
| 2018-03-09 | 2017-12-31 | 0001437749-18-004222 | EDGAR | 92K words |
| 2017-03-03 | 2016-12-31 | 0001437749-17-003702 | EDGAR | 94K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-12 | 2026-09-30 | 0001437749-26-036598 | EDGAR | 35K words |
| 2026-08-12 | 2026-06-30 | 0001437749-26-027316 | EDGAR | 35K words |
| 2025-11-12 | 2025-09-30 | 0001437749-25-034499 | EDGAR | 42K words |
| 2025-08-14 | 2025-06-30 | 0001437749-25-027002 | EDGAR | 40K words |
| 2025-05-14 | 2025-03-31 | 0001437749-25-016898 | EDGAR | 38K words |
| 2024-11-13 | 2024-09-30 | 0001437749-24-034965 | EDGAR | 44K words |
| 2024-08-14 | 2024-06-30 | 0001437749-24-026801 | EDGAR | 44K words |
| 2024-05-14 | 2024-03-31 | 0001437749-24-016694 | EDGAR | 43K words |
| 2023-11-14 | 2023-09-30 | 0001437749-23-031742 | EDGAR | 56K words |
| 2023-08-10 | 2023-06-30 | 0001437749-23-023124 | EDGAR | 55K words |
| 2023-05-10 | 2023-03-31 | 0001437749-23-013658 | EDGAR | 49K words |
| 2022-11-14 | 2022-09-30 | 0001437749-22-027307 | EDGAR | 62K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-12 | 0001437749-26-036555 | EDGAR | 3K words |
| 2026-08-12 | 0001437749-26-027311 | EDGAR | 3K words |
| 2026-03-23 | 0001437749-26-009299 | EDGAR | 3K words |
| 2026-03-16 | 0001437749-26-008318 | EDGAR | 1K words |
| 2026-03-13 | 0001437749-26-008217 | EDGAR | 1K words |
| 2025-11-12 | 0001437749-25-034446 | EDGAR | 3K words |
| 2025-10-24 | 0001437749-25-031731 | EDGAR | 19K words |
| 2025-10-22 | 0001437749-25-031468 | EDGAR | 1K words |
| 2025-10-16 | 0001437749-25-031162 | EDGAR | 1K words |
| 2025-09-10 | 0001437749-25-028787 | EDGAR | 24K words |
356 total filings indexed. 324 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001427925 |
| Ticker | TLPH |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.talphera.com |
| Listed | 2011-02-11 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TLPH (~200 tokens, structured JSON with cryptographic provenance)